Investor Presentation - First Six Months of 2021
64
Investor presentation First six months of 2021
A global phase 3a trial investigating oral semaglutide 50 mg in
obesity will be initiated H2 2021
Global trial planned to be initiated in H2 2021
Plan to include 660 patients with obesity
Oral semaglutide 50 mg
R
1:1
Placebo oral
Objective
To confirm superiority of oral semaglutide 50 mg vs. placebo on
weight loss in people with overweight or obesity
Primary endpoint
•
68 weeks
7 weeks
follow-up
Change in body weight from baseline (%)
•
Body weight reduction ≥ 5%
Inclusion criteria
• BMI: ≥27 kg/m² with ≥ 1 weight-related comorbidity, or
• BMI ≥30 kg/m²
•
Weight-related comorbidities are hypertension, dyslipidaemia,
obstructive sleep apnoea and CVD
OASIS: Oral Semaglutide treatment effect In people with Obesity; CVD: Cardiovascular disease; BMI: Body Mass Index
OASIS programme scope
.
Total of 1,000 patients across three trials: 1) A global (North
America and Europe), 2) Japanese and 3) Chinese trial
Novo Nordisk®View entire presentation